Europe - EPA:SAN - FR0000120578 - Common Stock
Taking everything into account, SAN scores 6 out of 10 in our fundamental rating. SAN was compared to 54 industry peers in the Pharmaceuticals industry. SAN scores excellent on profitability, but there are some minor concerns on its financial health. SAN is not valued too expensively and it also shows a decent growth rate. SAN also has an excellent dividend rating. This makes SAN very considerable for dividend investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 11.05% | ||
ROE | 19.73% | ||
ROIC | 13.84% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 23.59% | ||
PM (TTM) | 20.35% | ||
GM | 71.7% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | 2.21 | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.27 | ||
Quick Ratio | 0.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.45 | ||
Fwd PE | 9.96 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 20.92 | ||
EV/EBITDA | 11.09 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.62% |
EPA:SAN (10/17/2025, 7:00:00 PM)
86.43
+0.1 (+0.12%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.62% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.45 | ||
Fwd PE | 9.96 | ||
P/S | 3.1 | ||
P/FCF | 20.92 | ||
P/OCF | 18.51 | ||
P/B | 3.01 | ||
P/tB | 22.66 | ||
EV/EBITDA | 11.09 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 11.05% | ||
ROE | 19.73% | ||
ROCE | 16.7% | ||
ROIC | 13.84% | ||
ROICexc | 16.48% | ||
ROICexgc | 66.95% | ||
OM | 23.59% | ||
PM (TTM) | 20.35% | ||
GM | 71.7% | ||
FCFM | 14.83% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | 2.21 | ||
Debt/EBITDA | 0.75 | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | 250 | ||
Cash Conversion | 58.05% | ||
Profit Quality | 72.91% | ||
Current Ratio | 1.27 | ||
Quick Ratio | 0.94 | ||
Altman-Z | N/A |